What Is Allergy Immunotherapy? Every Form Compared and Explained
Allergy immunotherapy is the only treatment that modifies IgE-mediated allergic disease rather than suppressing symptoms. Five main forms exist: SCIT (allergy shots), SLIT tablets (FDA-approved), SLIT drops (used in 75+ countries), OIT for food allergy, and venom immunotherapy (95-98% protection). All share the Th2-to-Treg tolerance mechanism but differ in route and allergen coverage.
7 peer-reviewed sources
Allergy immunotherapy is a category of treatments that reprogram your immune system to tolerate specific allergens instead of overreacting to them. It is the only disease-modifying option in allergy medicine — all other treatments only suppress symptoms temporarily.
Allergy Immunotherapy: The Only Disease-Modifying Tier in Allergy Treatment
Allergy immunotherapy sits at the top of the allergy treatment hierarchy — above allergen avoidance, above antihistamines, above nasal corticosteroids. The distinction is fundamental: every other allergy treatment suppresses symptoms while the immune response remains unchanged. Immunotherapy, in all its forms, targets the root cause — training the immune system to tolerate the allergens it has learned to misidentify as threats.
The World Health Organization and the World Allergy Organization have formally recognized allergen immunotherapy as the only treatment that alters the natural course of allergic disease. In practice, this means patients who complete immunotherapy may reduce or eliminate their dependence on daily symptom medications — and benefit from durable immune changes that persist years after treatment ends.
Immunotherapy takes several forms. Subcutaneous immunotherapy (SCIT) — the classic allergy shots — has over 100 years of clinical evidence and remains the most broadly applicable option across allergen types. Sublingual immunotherapy (SLIT) delivers allergen extracts under the tongue — either as FDA-approved tablets for specific allergens or as custom-mixed drops used widely outside the US. Oral immunotherapy (OIT) addresses food allergies through a different mechanism and regulatory path. Venom immunotherapy treats life-threatening stinging insect allergy with a near-perfect protection rate.
No matter which form of immunotherapy you pursue, the first step is identifying which specific IgE-mediated sensitivities you have. Curex at-home allergy testing provides this diagnostic foundation through a finger-prick blood test covering 40+ environmental allergens — without requiring an office visit. A board-certified allergist then prescribes a personalized subcutaneous immunotherapy serum, sterile-compounded to USP <797> standards, that eligible maintenance patients self-administer as one weekly shot at home for $129/month — with the first injection and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand, so the immunotherapy form and formulation matched to your profile no longer requires weekly clinic trips.
Allergen immunotherapy is not one treatment — it is a category of treatments united by a common mechanism: inducing active immune tolerance to specific allergens. SCIT, SLIT, OIT, and venom IT all work through the same Th2-to-Treg pathway but differ in delivery route, FDA status, and allergen coverage. SCIT itself no longer means weekly clinic trips: with Curex, eligible maintenance patients self-administer the same subcutaneous serum at home for $129/month, with the first dose and every dose change supervised live over Zoom.
The Shared Mechanism Behind All Forms of Immunotherapy
Despite the differences in delivery route — subcutaneous injection, sublingual tablet, sublingual drop, oral dose, or subcutaneous venom injection — all forms of allergen immunotherapy converge on the same core immunological mechanism. Repeated exposure to carefully calibrated allergen doses, under non-inflammatory conditions, induces a fundamental shift in immune programming that converts allergic Th2 responses into active tolerance mediated by regulatory T cells.
Allergen Delivery to Antigen-Presenting Cells
In SCIT, allergen proteins reach subcutaneous dendritic cells directly via injection. In SLIT, they diffuse across oral mucosa and encounter specialized tolerogenic dendritic cells in the sublingual tissue. In OIT, allergens pass through the gut-associated lymphoid tissue. The route differs, but all deliver allergen to antigen-presenting cells (APCs) under non-dangerous conditions — the key distinction from natural allergen exposure.
Regulatory T-Cell Induction
APCs present processed allergen peptides to naive T cells in regional lymph nodes. Under the tolerogenic conditions created by controlled low-dose allergen exposure, naive T cells differentiate toward FOXP3+ regulatory T cells (Tregs) rather than Th2 effector cells. Tregs secrete IL-10 and TGF-beta, which suppress allergic inflammation at the cellular level. This Treg induction is detectable within weeks of starting any form of immunotherapy.
IgG4 Blocking Antibody Class Switch
As Tregs suppress Th2 signaling, B cells undergo a class switch away from IgE toward IgG4 antibody production. IgG4 blocking antibodies compete with allergen-specific IgE for binding to circulating allergen proteins — intercepting them before they can crosslink mast cell-bound IgE and trigger degranulation. IgG4 antibodies are non-inflammatory and do not activate complement, making them effective interceptors without causing secondary inflammation.
Long-Term Mast Cell Desensitization
Over the full treatment course, mast cell and basophil thresholds for allergen-triggered activation rise progressively. The cells that previously released histamine at minimal allergen exposure now require much higher stimulation to degranulate. Combined with the IgG4 interception upstream, this creates multiple layers of protection that persist years after treatment stops — evidence that the immune changes are structural, not just suppressive.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youAll Forms of Allergy Immunotherapy: Side-by-Side Comparison
The five main forms of allergen immunotherapy share a common mechanism but differ dramatically in delivery method, FDA status, allergen coverage, time commitment, and cost. The table below summarizes each form to help you understand the landscape — but your allergist should guide the final decision based on your specific allergen profile, symptom severity, and lifestyle factors.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Allergy Shots (Curex SCIT)Best | Pooled SMD -0.73 across 51 RCTs; 50-80% of patients achieve meaningful improvement | 3-5 years | $3,000-10,000 insured; up to $15,000 self-pay | With Curex, at-home weekly self-injection; first dose and every dose change supervised live over Zoom; brief self-observation after each dose | Local reactions 30-80%; systemic reactions 0.1-0.2% per injection, mostly mild; with Curex a prescribed epinephrine auto-injector is confirmed on hand before the first dose |
SLIT Drops (Custom-Mixed) | Strong European evidence base of 60+ RCTs; comparable to SCIT for studied allergens | 3-5 years | $2,340-3,500 | Daily drops at home; no clinic visits, no needles, no observation period | Primarily oral/sublingual local reactions; systemic reactions very rare; no epinephrine requirement at home |
SLIT Tablets (FDA-Approved) | FDA-approved for grass (Grastek), ragweed (Ragwitek), dust mite (Odactra); strong evidence for covered allergens | 3-5 years | $5,000-15,000 depending on insurance | Daily sublingual tablets at home after first supervised dose in-office | Mild-to-moderate local reactions; not approved for patients with multiple allergen sensitizations outside approved indications |
OIT (Oral Immunotherapy) | FDA-approved Palforzia for peanut allergy in ages 4-17; achieves desensitization in most participants | Ongoing maintenance often required to preserve protection | $10,000-30,000 depending on program | Daily oral doses at home after supervised initial escalation; requires continued daily dosing | Higher adverse event rate than inhalant IT; risk of GI symptoms and eosinophilic esophagitis; treatment at specialized centers |
Venom Immunotherapy (VIT) | 95-98% protection rate for Hymenoptera-allergic patients — the most effective immunotherapy form | 3-5 years standard; some patients require lifelong maintenance | $3,000-8,000 insured | Same injection schedule as SCIT; clinic visits required for build-up and maintenance | Higher systemic reaction rate during build-up than inhalant SCIT; managed in clinic with epinephrine available |
- Efficacy
- Pooled SMD -0.73 across 51 RCTs; 50-80% of patients achieve meaningful improvement
- Duration
- 3-5 years
- Cost (5yr)
- $3,000-10,000 insured; up to $15,000 self-pay
- Convenience
- With Curex, at-home weekly self-injection; first dose and every dose change supervised live over Zoom; brief self-observation after each dose
- Safety
- Local reactions 30-80%; systemic reactions 0.1-0.2% per injection, mostly mild; with Curex a prescribed epinephrine auto-injector is confirmed on hand before the first dose
- Efficacy
- Strong European evidence base of 60+ RCTs; comparable to SCIT for studied allergens
- Duration
- 3-5 years
- Cost (5yr)
- $2,340-3,500
- Convenience
- Daily drops at home; no clinic visits, no needles, no observation period
- Safety
- Primarily oral/sublingual local reactions; systemic reactions very rare; no epinephrine requirement at home
- Efficacy
- FDA-approved for grass (Grastek), ragweed (Ragwitek), dust mite (Odactra); strong evidence for covered allergens
- Duration
- 3-5 years
- Cost (5yr)
- $5,000-15,000 depending on insurance
- Convenience
- Daily sublingual tablets at home after first supervised dose in-office
- Safety
- Mild-to-moderate local reactions; not approved for patients with multiple allergen sensitizations outside approved indications
- Efficacy
- FDA-approved Palforzia for peanut allergy in ages 4-17; achieves desensitization in most participants
- Duration
- Ongoing maintenance often required to preserve protection
- Cost (5yr)
- $10,000-30,000 depending on program
- Convenience
- Daily oral doses at home after supervised initial escalation; requires continued daily dosing
- Safety
- Higher adverse event rate than inhalant IT; risk of GI symptoms and eosinophilic esophagitis; treatment at specialized centers
- Efficacy
- 95-98% protection rate for Hymenoptera-allergic patients — the most effective immunotherapy form
- Duration
- 3-5 years standard; some patients require lifelong maintenance
- Cost (5yr)
- $3,000-8,000 insured
- Convenience
- Same injection schedule as SCIT; clinic visits required for build-up and maintenance
- Safety
- Higher systemic reaction rate during build-up than inhalant SCIT; managed in clinic with epinephrine available
For patients seeking immunotherapy without weekly clinic visits, Curex delivers the most broadly evidenced form — subcutaneous immunotherapy — as one weekly at-home shot for $129/month. The personalized serum is sterile-compounded to USP <797> standards and overseen by a board-certified allergist, with your first injection and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand, so eligible maintenance patients get the same allergy shots clinics use without the office commute.
See if at-home shots are right for youFrequently asked questions
What is the difference between allergy shots and allergy drops?
Allergy shots (SCIT) and allergy drops (SLIT) share the same goal — inducing immune tolerance to specific allergens — but differ in delivery route and practical logistics. Shots are injected subcutaneously and traditionally involve weekly clinic build-up visits with a 30-minute post-injection observation; with an at-home program like Curex, eligible maintenance patients self-inject weekly at home for $129/month, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand. Drops are placed under the tongue daily at home with no injections. Both treat the same Th2-to-Treg tolerance pathway. SCIT has the larger published evidence base (100+ years, 51+ RCTs for rhinitis); SLIT drops have 60+ European RCTs and are used in 75+ countries but remain off-label in the US. SLIT tablets are FDA-approved for specific allergens (grass, ragweed, dust mite) but do not cover custom multi-allergen profiles.
Is allergy immunotherapy safe?
Allergy immunotherapy has a strong safety record when administered by a board-certified allergist following established protocols. For SCIT, local injection-site reactions occur in 30-80% of injections and are expected and manageable. Systemic reactions occur in 0.1-0.2% of SCIT injections — most are mild and respond to antihistamines. Fatal anaphylaxis from SCIT is extremely rare, estimated at less than 1 per 2.5 million injections per AAAAI surveillance data. SLIT forms have a more favorable safety profile — systemic reactions are very rare, and there are no documented fatal reactions from SLIT for inhalant allergens. Venom immunotherapy has a higher build-up phase systemic reaction rate but also carries the strongest efficacy evidence of any IT form.
How long does allergy immunotherapy take to work?
Most patients receiving any form of allergen immunotherapy begin to notice symptom improvement within 3-6 months, with maximum benefit typically reached at 12-18 months of consistent treatment. SCIT's build-up phase takes 3-6 months to reach maintenance dose, during which early immune changes are occurring but clinical symptoms may not yet be dramatically reduced. SLIT forms may show early symptom effects slightly earlier due to the tolerogenic oral mucosal environment, though head-to-head timeline data between SCIT and SLIT is limited. Both require 3-5 years of total treatment to maximize long-lasting benefit. Stopping early reduces the durability of the immune changes achieved.
Does insurance cover allergy immunotherapy?
Coverage for allergy immunotherapy varies significantly by form and insurer. SCIT (allergy shots) is covered by most major US health insurers including UnitedHealthcare, Blue Cross Blue Shield, Aetna, and Cigna, typically with prior authorization and requirements for documented treatment failure on antihistamines or nasal steroids. FDA-approved SLIT tablets (Grastek, Ragwitek, Odactra) are covered by many insurers but may require step therapy. Custom SLIT drops are off-label in the US, and most major insurers do not cover off-label compounded pharmaceuticals — though some regional plans and HSA/FSA accounts can be used. Venom immunotherapy is generally covered when medically necessary for documented stinging insect anaphylaxis.
Can children receive allergy immunotherapy?
Yes, children can receive allergy immunotherapy. SCIT is commonly initiated in children as young as 5 years old, though some allergists may start younger in cases of severe allergic asthma or insect sting allergy. The PAT study (Moller et al., JACI, 2002) demonstrated that SCIT initiated in children with allergic rhinitis significantly reduced the risk of developing asthma over a 7-year follow-up — providing a compelling argument for early treatment. SLIT tablets (Grastek for grass, Odactra for dust mite) have pediatric indications. OIT via Palforzia is approved for ages 4-17 for peanut allergy. Children often respond well to immunotherapy and may achieve longer-lasting benefits due to a longer window for immune reprogramming during development.
What are the FDA-approved forms of allergen immunotherapy?
FDA-approved allergen immunotherapy forms in the US include SCIT (allergy shots using FDA-licensed allergen extract biologics), three SLIT tablets (Grastek for Timothy grass pollen, approved 2014; Ragwitek for short ragweed, approved 2014; Odactra for dust mite D. farinae and D. pteronyssinus, approved 2017), and Palforzia (peanut OIT) for ages 4-17, approved 2020. Custom-mixed SLIT drops, despite strong international evidence, remain off-label in the US because the FDA has not approved the specific custom-compounded drop products, even though the individual allergen extracts are FDA-licensed. This off-label status is why SLIT drops are widely used globally but less common in US insurance-covered plans.
What happens if you don't complete allergy immunotherapy?
Stopping allergy immunotherapy before completing the recommended 3-5 year course reduces the durability of immune benefits achieved. Patients who stop during the build-up phase before reaching maintenance dose lose most tolerance gains quickly. Those who complete 2-3 years of maintenance immunotherapy retain more lasting benefit but are less likely to achieve the durable protection seen with a full course. Clinical guidelines recommend discussing any decision to discontinue with your allergist, who may taper the schedule or plan a structured discontinuation. The analogy is completing a course of physical therapy — stopping halfway through reduces how long the gains last, even if you felt better at the midpoint.
Is allergy immunotherapy the same as a cure for allergies?
Allergy immunotherapy is not a guaranteed permanent cure, but it is the closest treatment to disease modification that allergy medicine currently offers. Clinical evidence shows benefits persisting 3-12 years after stopping a complete treatment course — a meaningful difference from symptom medications which provide zero lasting change. The WHO and WAO formally recognize immunotherapy as the only treatment that alters the natural course of allergic disease. However, some patients experience gradual return of symptoms years after stopping, particularly if re-exposure to high allergen concentrations is sustained over time. A small number of patients choose to continue low-dose maintenance beyond the standard 5 years to prolong their benefits.
Related Articles
How Long Do Allergy Shots Take? Trial vs Reality | Curex
How long do allergy shots take to work? Trials show 12-month benefit, but only 23% complete 3 years. Real-world vs clinical data guide.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT trains your immune system to tolerate allergens over 3-5 years. 85-90% of patients see significant improvement.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreAllergy Shots: Complete SCIT Guide for Patients | Curex
Allergy shots (SCIT) reduce symptoms by 33-85% over 3-5 years. Learn how they work, what they cost, and who qualifies for this disease-modifying treatment.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.